Professor Ian Frazer FRS

Professor Ian Frazer
MB, ChB Edin., MD Melb.,
CEO and Director of Research, TRI Pty Ltd
Research Leader, Epithelial Cancer Division, UQDI

Email: Professor Ian Frazer
Telephone: +61 7 3346 1905

Biography

Professor Ian Frazer was trained as a renal physician and clinical immunologist in Edinburgh, Scotland before emigrating in 1981 to Melbourne, Australia to pursue studies in viral immunology and autoimmunity at the Walter and Eliza Hall Institute of Medical Research with Professor Ian Mackay. In 1985 he moved to Brisbane to take up a teaching post with the University of Queensland and was appointed Director of the Centre for Immunology and Cancer Research (now known as The University of Queensland Diamantina Institute) in 1991. Professor Frazer is Chief Executive Officer and Director of Research at the Translational Research Institute (TRI) Pty Ltd.

Professor Frazer holds research funding from several Australian and US funding bodies. He is a Director of a biotechnology start-up company, Coridon, with an interest in optimising and targeting polynucleotide vaccine protein expression. He is immediate past President of the Cancer Council Australia, Chairman of the Australian Cancer Research Foundation's Medical Research Advisory Committee, and Deputy Chair of the International Agency for Research on Cancer Scientific Advisory Committee. He won the 2005 CSIRO Eureka Prize for Leadership in Science and was selected as Queenslander of the Year, and Australian of the Year in 2006. He was also awarded the 2008 Prime Minister's Prize for Science, the 2008 Balzan Prize for Preventive Medicine, and the 2009 Honda Prize, and in May 2011, was elected as a Fellow of the esteemed Royal Society of London. Professor Frazer teaches immunology to undergraduate and graduate students of the University.

Research Interests

Professor Frazer's current research interests include immunoregulation and immunotherapeutic vaccines for papillomavirus associated cancers.

Research Projects

• Regulation of effector T cells by the innate immune response
• Immunotherapy for HPV associated disease
• Cervical cancer control in Vanuatu

10 Recent Publications

1. Improving the reach of vaccines to low-resource regions, with a needle-free vaccine delivery device and long-term thermostabilization. Chen X, Fernando GJ, Crichton ML, Flaim C, Yukiko SR, Fairmaid EJ, Corbett HJ, Bover CA, Ansaldo AB, Frazer IH, Brown LE, Kendall MA.
   J Control Release. 2011 Mar 1. [Epub ahead of print] PMID: 21371510.

2. Human papillomavirus 16 E7 protein inhibits interferon-?-mediated enhancement of keratinocyte antigen processing and T-cell lysis. Zhou F, Leggatt GR, Frazer IH. FEBS J. 2011 Apr;278(6):955-63. doi: 10.1111/j.1742-4658.2011.08011.x. Epub 2011 Feb 5. PMID:
   21232015.

3. Regulation of immune responses to HPV infection and during HPV-directed immunotherapy. Bhat P, Mattarollo SR, Gosmann C, Frazer IH, Leggatt GR. Immunol Rev. 2011 Jan;239(1):85-98. doi: 10.1111/j.1600-065X.2010.00966.x. PMID: 21198666.

4. Prevention and Treatment of Papillomavirus-Related Cancers Through Immunization. Frazer IH, Leggatt GR, Mattarollo SR. Annu Rev Immunol. 2010 Apr 5. [Epub ahead of print] PMID: 21166538.

5. Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model. Corbett HJ, Fernando GJ, Chen X, Frazer IH, Kendall MA. PLoS One. 2010 Oct 18;5(10):e13460. PMID: 20976136.

6. Evaluation of a cervical cancer screening program based on HPV testing and LLETZ excision in a low resource setting. McAdam M, Sakita J, Tarivonda L, Pang J, Frazer IH. PLoS One. 2010 Oct 7;5(10):e13266. PMID: 20949059.

7. Antigen-specific CD8 T cells can eliminate antigen-bearing keratinocytes with clonogenic potential via an IFN-gamma-dependent mechanism. De Kluyver RL, Moritz L, Harris CA, Azukizawa H, Frazer IH. J Invest Dermatol. 2010 Jul;130(7):1841-8. Epub 2010 Mar 18. PMID: 20237491.

8. Antigen-specific CD4 cells assist CD8 T-effector cells in eliminating keratinocytes. Broom JK, Lew AM, Azukizawa H, Kenna TJ, Leggatt GR, Frazer IH. J Invest Dermatol. 2010 Jun;130(6):1581-9. Epub 2010 Feb 11. PMID: 20147961.

9. Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control. Ferreira MA, Mangino M, Brumme CJ, Zhao ZZ, Medland SE, Wright MJ, Nyholt DR, Gordon S, Campbell M, McEvoy BP, Henders A, Evans DM, Lanchbury JS, Pereyra F; International HIV Controllers Study, Walker BD, Haas DW, Soranzo N, Spector TD, de Bakker PI, Frazer IH, Montgomery GW, Martin NG. Am J Hum Genet. 2010 Jan;86(1):88-92. Epub 2009 Dec 31. PMID: 20045101.

10. Invariant NKT cells in hyperplastic skin induce a local immune suppressive environment by IFN-gamma production. Mattarollo SR, Rahimpour A, Choyce A, Godfrey DI, Leggatt GR, Frazer IH. J Immunol. 2010 Feb 1;184(3):1242-50. Epub 2009 Dec 18. PMID: 20028654.

Lab members
 

Legacy

Dr Robert Tindle (Research Fellow 1987-1993). Now: Director of the Sir Albert Sakzewski Research Laboratories, Brisbane, Australia.
Dr Linda Selvey (PhD Student 1988-1991). Now: CEO of Greenpeace Australia.
Dr XiaoSong Liu (Research Officer 2001-2006). Now: Senior Lecturer in Immunology, The University of Newcastle.
Dr David Whitehead (Honours Student 1988). Now: Senior Research Fellow, Queensland Institute of Medical Research.
 

On this site